Walking the path of treatable traits in interstitial lung diseases

被引:0
|
作者
Francesco Amati
Paolo Spagnolo
Christopher J. Ryerson
Justin M. Oldham
Andrea Gramegna
Anna Stainer
Marco Mantero
Nicola Sverzellati
Donato Lacedonia
Luca Richeldi
Francesco Blasi
Stefano Aliberti
机构
[1] Humanitas University,Department of Biomedical Sciences
[2] IRCCS Humanitas Research Hospital,Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health
[3] Respiratory Unit,Department of Medicine
[4] University of Padova,Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine
[5] University of British Columbia and Centre for Heart Lung Innovation,Department of Pathophysiology and Transplantation
[6] St. Paul’s Hospital,Unit of Scienze Radiologiche, Department of Medicine and Surgery
[7] University of Michigan,Department of Medical and Occupational Sciences, Institute of Respiratory Disease
[8] Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico,undefined
[9] Respiratory Unit and Cystic Fibrosis Adult Center,undefined
[10] Università degli Studi di Milano,undefined
[11] University of Parma,undefined
[12] Università degli Studi di Foggia,undefined
[13] Fondazione Policlinico A. Gemelli IRCCS,undefined
[14] Università Cattolica del Sacro Cuore,undefined
来源
Respiratory Research | / 24卷
关键词
Treatable traits; Biomarkers; Endotype; Phenotype; Interstitial lung diseases; Personalized medicine; Artificial intelligence;
D O I
暂无
中图分类号
学科分类号
摘要
Interstitial lung diseases (ILDs) are complex and heterogeneous diseases. The use of traditional diagnostic classification in ILD can lead to suboptimal management, which is worsened by not considering the molecular pathways, biological complexity, and disease phenotypes. The identification of specific “treatable traits” in ILDs, which are clinically relevant and modifiable disease characteristics, may improve patient’s outcomes. Treatable traits in ILDs may be classified into four different domains (pulmonary, aetiological, comorbidities, and lifestyle), which will facilitate identification of related assessment tools, treatment options, and expected benefits. A multidisciplinary care team model is a potential way to implement a “treatable traits” strategy into clinical practice with the aim of improving patients’ outcomes. Multidisciplinary models of care, international registries, and the use of artificial intelligence may facilitate the implementation of the “treatable traits” approach into clinical practice. Prospective studies are needed to test potential therapies for a variety of treatable traits to further advance care of patients with ILD.
引用
收藏
相关论文
共 50 条
  • [1] Walking the path of treatable traits in interstitial lung diseases
    Amati, Francesco
    Spagnolo, Paolo
    Ryerson, Christopher J.
    Oldham, Justin M.
    Gramegna, Andrea
    Stainer, Anna
    Mantero, Marco
    Sverzellati, Nicola
    Lacedonia, Donato
    Richeldi, Luca
    Blasi, Francesco
    Aliberti, Stefano
    RESPIRATORY RESEARCH, 2023, 24 (01)
  • [2] The prevalence of treatable traits in patients with fibrosing interstitial lung disease
    Lawler, C.
    Fermoyle, C.
    Troy, L.
    Glenn, L.
    Jee, A.
    Teoh, A.
    Jo, H.
    Jackson, D.
    Webster, S.
    Geis, M.
    He, T.
    Yuan, T.
    Harrison, M.
    Khor, Y.
    Corte, T.
    RESPIROLOGY, 2024, 29 : 218 - 218
  • [3] First Report of the Prevalence at Baseline and after 1-Year Follow-Up of Treatable Traits in Interstitial Lung Diseases
    Amati, Francesco
    Stainer, Anna
    Maruca, Giacomo
    De Santis, Maria
    Mangiameli, Giuseppe
    Torrisi, Chiara
    Bossi, Paola
    Polelli, Veronica
    Blasi, Francesco
    Selmi, Carlo
    Marulli, Giuseppe
    Balzarini, Luca
    Terracciano, Luigi Maria
    Gatti, Roberto
    Aliberti, Stefano
    BIOMEDICINES, 2024, 12 (05)
  • [4] Progressive fibrosing interstitial lung disease: treatable traits and therapeutic strategies
    Wongkarnjana, Amornpun
    Scallan, Ciaran
    Kolb, Martin R. J.
    CURRENT OPINION IN PULMONARY MEDICINE, 2020, 26 (05) : 436 - 442
  • [5] Breathomics and treatable traits for chronic airway diseases
    Brinkman, Paul
    Maitland-van der Zee, Anke-Hilse
    Wagener, Ariane H.
    CURRENT OPINION IN PULMONARY MEDICINE, 2019, 25 (01) : 94 - 100
  • [6] Biomarkers in Interstitial lung diseases
    Nathan, Nadia
    Corvol, Harriet
    Amselem, Serge
    Clement, Annick
    PAEDIATRIC RESPIRATORY REVIEWS, 2015, 16 (04) : 219 - 224
  • [7] Treatable traits in acute exacerbations of chronic airway diseases
    McDonald, Vanessa M.
    Osadnik, Christian R.
    Gibson, Peter G.
    CHRONIC RESPIRATORY DISEASE, 2019, 16
  • [8] Treatable traits: toward precision medicine of chronic airway diseases
    Agusti, Alvar
    Bel, Elisabeth
    Thomas, Mike
    Vogelmeier, Claus
    Brusselle, Guy
    Holgate, Stephen
    Humbert, Marc
    Jones, Paul
    Gibson, Peter G.
    Vestbo, Jorgen
    Beasley, Richard
    Pavord, Ian D.
    EUROPEAN RESPIRATORY JOURNAL, 2016, 47 (02) : 410 - 419
  • [9] Autoantibodies in Interstitial Lung Diseases
    Bostanoglu, Asli
    Celik, Gokhan
    EUROPEAN RESPIRATORY JOURNAL, 2021, 58
  • [10] Adipokines in interstitial lung diseases
    Zielinski, M.
    Chwalba, A.
    Jastrzebski, D.
    Ziora, D.
    RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY, 2023, 315